TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
about
c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaBThe lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cellsEctopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosisIncreased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAILSurface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cellsStructure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactionsMechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell typesMolecular evidence for the nuclear localization of FADDHonokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivoFollowing a TRAIL: update on a ligand and its five receptorsRole of Fas-associated death domain-containing protein (FADD) phosphorylation in regulating glucose homeostasis: from proteomic discovery to physiological validationApoptosis and the airway epitheliumA set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.Network motif-based method for identifying coronary artery diseaseEarly therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopyCoordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells.Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.Identification of new IκBα complexes by an iterative experimental and mathematical modeling approach.The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis.Prognostic significance of TMEM16A, PPFIA1, and FADD expression in invasive ductal carcinoma of the breastSynergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.Regulation of Fas-mediated apoptosis in CD2-fas transgenic mice.Signaling by tumor necrosis factor receptors: pathways, paradigms and targets for therapeutic modulation.Tissue-specific Bcl-2 protein partners in apoptosis: An ovarian paradigm.Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKTThe death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.Inflammation in diabetic kidney diseaseStatins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome.Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function.Inducible resistance to Fas-mediated apoptosis in B cells.Apoptosis and its clinical impact.CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells.Fas receptor-mediated apoptosis: a clinical application?
P2860
Q22010238-647B8922-367C-4300-BBE1-59DF2C47F52EQ22254033-2F2883EB-5FE2-46E1-9F89-785ABE6B2303Q24304892-C59F5166-B0F2-43DA-B551-CB865A9076EBQ24554360-73EA8C54-C47E-4269-B94C-BFA44ABD397FQ24810732-61BB9A15-11C7-4A13-AAB4-68C093614CD8Q27677202-C98104BB-10E0-408E-BCCB-B27F6D59DB22Q28140698-A2CFADD9-FE7C-4E45-B59F-A6A6A38F468AQ28180414-8AA3B4A5-4985-498A-B74F-2CB011D8C57BQ28180577-361F2B01-DBC8-46BD-89D1-984BAAE4FE67Q28292767-879271E8-E0C5-4E80-A262-8DC20392BE4FQ28293997-AD4949B3-A0AB-44FD-86F0-54BF275C688AQ28741414-B9867039-39E6-4E29-ABA9-2B1ABC2EA01FQ30361915-6114CB37-17D0-4C9F-93ED-01B16F3B1A81Q30380892-5E3B0630-E4FE-4B2D-A389-3B5B3F2C6C0EQ30682911-8605E06B-716B-42C6-8892-926210912D87Q30896561-08CAE370-54DD-4ACD-916A-507282DBBA3EQ31145220-F389E74F-0F70-487E-A1A7-78D02BA4910AQ31154854-CC484A93-E077-4B38-B87A-7ADB07ADD4B4Q33292139-8FFF59E1-C28A-4955-8BA0-7291995E8BA3Q33637350-69A01262-21C6-4889-8950-266C8DE5D610Q33680928-C6F2AB5D-DDE1-4205-9E4A-23655AC54AB9Q33729242-7C398613-3EE7-45DF-AAB6-7C7771536C53Q33782305-74EE1D2C-F103-45AC-B8FD-40BADA5CD9C9Q33811729-E5DB826A-5CB3-41CB-807F-93ABCDDE075BQ33811753-608F2279-8332-44BC-B25F-D40D7545E76EQ33881268-2878400D-FAC3-4857-8B65-D5FFE62AF17EQ33910907-24AC785C-259D-4996-AA2B-ABAEAE30D15EQ33912038-0F4CCD81-B364-47C7-BD61-F997430756DFQ33916314-E3F97A61-3A23-4D48-A01F-186E6E3F928CQ33965358-ABD05CD9-1FBE-4AC7-B923-E54AE12DEC1BQ34023543-01920203-F6F4-453C-A197-6F442E42EB99Q34036983-5E5B6A48-6AFE-4BBD-8C8E-5C3D20FD29D8Q34045050-884933D7-EBD7-4403-856D-013D116D63F1Q34071289-C8E53748-E817-4354-AD14-EB6463E002FEQ34146806-C00A3114-C9B0-4BE6-A4E6-9841B02A8463Q34214558-3F410EFC-1181-4946-994A-1B88A42853E7Q34266298-7108DB4D-FB15-444D-ABFC-0EF84718BC42Q34272896-90235E8B-B8D5-4F38-A89B-ACC150E4ABC1Q34333852-B882AAEF-A076-40A3-8263-75AA2A072B7FQ34495634-B5DF6E17-5F6D-432B-898C-C6F41ED773AA
P2860
TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@ast
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@en
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@nl
type
label
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@ast
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@en
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@nl
prefLabel
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@ast
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@en
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@nl
P2093
P3181
P1433
P1476
TRAIL receptors 1 (DR4) and 2 ...... optosis and activate NF-kappaB
@en
P2093
P304
P3181
P356
10.1016/S1074-7613(00)80401-X
P407
P577
1997-12-01T00:00:00Z